|
시장보고서
상품코드
2017784
파이로젠 및 엔도톡신 검사 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)Pyrogen And Endotoxin Testing Market Size, Share & Trends Analysis Report By Product, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
파이로젠 및 엔도톡신 검사 시장 요약
세계의 파이로젠 및 엔도톡신 검사 시장 규모는 2025년에 25억 6,000만 달러로 추정되며, 2033년까지 44억 6,000만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 7.22%로 성장할 것으로 예상됩니다. 제약 및 생명공학 산업에서 파이로젠 및 엔도톡신 검사 제품에 대한 수요 증가는 시장 성장의 주요 촉진요인으로 작용하고 있습니다.
이러한 산업의 급속한 성장과 더불어 새로운 치료제의 출시가 증가함에 따라 파이로젠 및 엔도톡신 검사 제품에 대한 수요가 더욱 증가할 것으로 예상됩니다. 이러한 성장은 의약품 및 바이오테크놀러지 제품의 안전성과 유효성을 보장하는 데 있어 파이로젠 및 엔도톡신 검사가 매우 중요한 역할을 하고 있음을 보여줍니다.
일부 규제 당국과 정부는 파이로젠 및 내독소 시험에 대한 교육 및 인식 개선을 위해 다양한 노력을 기울이고 있습니다. 세계 각국 정부의 노력은 이러한 전환을 가속화하는 데 있어 매우 중요합니다. 2024년 6월, 유럽약전(Ph. Eur.) 위원회의 179차 회의는 동물복지와 현대적 발열원-내독소 시험의 실천에 중요한 진전을 가져왔습니다. 이번 회의에서 위원회는 57개의 개정된 텍스트에서 토끼 발열원 시험(RPT)을 삭제하고, 발열원성에 대한 종합적인 새로운 일반 장을 도입했습니다. 이번 결정으로 모든 Ph. Eur. 교과서에서 RPT 요건이 사실상 폐지되어 단세포 활성화 시험(MAT)과 같은 in vitro 조사 방법으로의 전환이 확고히 이루어졌습니다.
기술 발전으로 인해 시험의 민감도, 정확도 및 진화하는 규제 표준에 대한 적합성이 향상됨에 따라 파이로젠 및 엔도톡신 검사 산업의 규모가 눈에 띄게 확대되고 있습니다. 의약품, 생물학적 제제, 백신 및 의료기기의 안전성 확보에 대한 관심이 높아지면서 내독소 및 비내독소 발열 물질을 모두 검출할 수 있는 첨단 테스트 플랫폼에 대한 수요가 증가하고 있습니다. 업계는 기존의 동물을 이용한 방법에서 보다 빠른 결과 도출과 재현성 향상을 실현하는 최신 in vitro 기술로 점차 전환하고 있습니다. 예를 들어, 2025년 5월 Minerva Biolabs GmbH는 단핵구 활성화 테스트(MAT)와 디지털 PCR을 통합한 차세대 발열 물질 검출 플랫폼 'NAT-MAT 시스템'을 발표했습니다. 이 시스템은 IL-1B와 TNF-α를 포함한 사이토카인의 유전자 발현을 측정하여 기존의 ELISA 기반 MAT 분석과 비교하여 보다 민감하고 빠른 검출이 가능합니다. 이러한 혁신은 의약품 품질 관리 과정에서 첨단 분자 및 세포 기반 진단 기술의 적용 범위가 확대되고 있음을 보여줍니다.
2026년 1월, BETMAT Biotechnology는 의약품 및 의료기기 제조의 진화하는 품질 관리 요구 사항을 충족하도록 설계된 고성능의 지속가능한 내독소 검사 서비스를 시작했습니다. 이 새로운 서비스는 국제 약전 표준을 준수하는 신뢰할 수 있는 세균성 내독소 검사(BET) 솔루션을 제공하는 데 중점을 두고 있으며, 동시에 실험실 검사의 지속가능성을 위한 노력에 도움을 줄 것입니다. 이번 서비스 출시는 의약품 제조에 있어 효율적이고 표준화된 환경 친화적인 내독소 검출 기술에 대한 수요 증가를 반영하고 있습니다. BETMAT의 검사 인프라는 USP, EP, BP, ChP 등 세계 약전 요구사항에 부합하는 고도의 자동화 장비와 엄격한 품질 관리 시스템을 갖추고 있어 추적성을 확보한 신뢰할 수 있는 결과를 보장합니다.
또한, 통합 테스트 플랫폼의 개발로 전체 제약 제조 워크플로우에서 자동화되고 표준화된 발열 물질 검출 솔루션의 역할이 강화되고 있습니다. NAT-MAT 플랫폼에는 즉시 사용 가능한 대식세포, 핵산 추출 키트 및 삼중 디지털 PCR 분석이 포함되어 있어 품질 관리 및 공정 내 모니터링 모두에서 신뢰할 수 있는 자동화된 테스트가 가능합니다. 이러한 발전은 효율성을 높이고 실험실에서 수작업을 줄일 수 있는 종합적인 테스트 시스템으로의 전환이 진행되고 있음을 반영합니다.
또한, 이러한 기술이 완전한 발열원 및 내독소 시험을 지원할 수 있는 능력은 토끼를 이용한 발열원 시험과 같은 전통적인 동물 실험 방법을 점차적으로 대체할 수 있는 기회를 창출하고 있습니다. 규제 당국과 이해관계자들이 동물을 사용하지 않는 시험 방법을 점점 더 많이 추진하고 있는 가운데, 첨단 체외 발열원 검출 기술의 채택이 확대될 것으로 예상되며, 이는 시장 범위를 넓히고 내독소 및 발열원 내독소 시험 솔루션의 지속적인 혁신을 촉진할 것으로 보입니다. 혁신이 촉진될 것으로 예상됩니다.
제품 개발을 위한 정부 및 제조 기업의 연구개발(R&D) 투자 증가는 시장 성장에 기여하는 주요 요인 중 하나입니다. 신제품 개발 및 출시는 제조업체가 업계에서 우위를 유지하고 최대 수익 점유율을 확보하기 위해 채택하는 중요한 전략입니다. 유럽제약산업협회연합회(EFPIA)의 발표에 따르면, 2022년 유럽 연구개발형 제약 업계는 연구개발(R&D)에 약 486억 5,000만 달러를 투자할 것으로 예상했습니다. 따라서 예측 기간 동안 파이로젠 및 엔도톡신 검사 제품에 대한 수요가 급증할 것으로 예상됩니다.
또한, 발열원 및 내독소 검사 산업은 치료용 의약품에 대한 수요 증가에 힘입어 성장하고 있습니다. 많은 기업들이 신약 개발에 적극적으로 나서고 있습니다. 예를 들어, 2023년 FDA는 55개의 신약을 승인했습니다. 의약품 개발 시 발열원 검사는 주사제 등 의약품에 포함된 발열원의 유무를 평가하는 것입니다. 또한, 의약품의 무균성이 그 의약품이 발열원을 포함하지 않는다는 것을 의미하지는 않습니다. 따라서 무균이 기대되는 의약품이라도 환자의 발열 반응을 억제하기 위해 발열원 유무를 검사해야 합니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 파이로젠 및 엔도톡신 검사 시장 : 변수, 동향, 범위
제4장 파이로젠 및 엔도톡신 검사 시장 : 제품별 추정·동향 분석
제5장 파이로젠 및 엔도톡신 검사 시장 : 기술별 추정·동향 분석
제6장 파이로젠 및 엔도톡신 검사 시장 : 용도별 추정·동향 분석
제7장 파이로젠 및 엔도톡신 검사 시장 : 최종사용별 추정·동향 분석
제8장 파이로젠 및 엔도톡신 검사 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSM 26.05.12Pyrogen & Endotoxin Testing Market Summary
The global pyrogen and endotoxin testing market size was estimated at USD 2.56 billion in 2025 and is projected to reach USD 4.46 billion by 2033, growing at CAGR of 7.22% from 2026 to 2033. The increasing demand for pyrogen and endotoxin testing products in the pharmaceutical and biotechnology industries is a significant driver of market growth.
The rapid expansion of these industries, coupled with the rising number of new therapeutic launches, is expected to propel the demand for pyrogen and endotoxin testing products further. This growth highlights the critical role of pyrogen and endotoxin testing in ensuring the safety and efficacy of pharmaceutical and biotechnological products.
Several regulatory bodies and governments are taking various initiatives to train and create awareness about pyrogen and endotoxin testing. Government initiatives worldwide are pivotal in accelerating this transition. In June 2024, the 179th session of the European Pharmacopoeia (Ph. Eur.) Commission marked a significant advancement for animal welfare and contemporary pyrogen and endotoxin testing practices. During this session, the Commission approved the removal of the Rabbit Pyrogen Test (RPT) from 57 revised texts and introduced a comprehensive new general chapter on Pyrogenicity. This decision effectively abolished the RPT requirement across all Ph. Eur. texts, solidifying the transition toward in vitro testing methodologies, such as the Monocyte Activation Test (MAT).
The scope of the pyrogen and endotoxin testing industry is expanding significantly as technological advancements improve testing sensitivity, accuracy, and compliance with evolving regulatory standards. Increasing emphasis on ensuring the safety of pharmaceuticals, biologics, vaccines, and medical devices has driven the demand for advanced testing platforms capable of detecting both endotoxin and non-endotoxin pyrogens. The industry is gradually transitioning from traditional animal-based methods toward modern in vitro technologies that offer faster turnaround times and improved reproducibility. For instance, in May 2025, Minerva Biolabs GmbH introduced the NAT-MAT system, a next-generation pyrogen-detection platform that integrates the Monocyte Activation Test (MAT) with digital PCR. The system measures cytokine gene expression, including IL-1B and TNF-a, enabling more sensitive and rapid detection compared to conventional ELISA-based MAT assays. Such innovations highlight the expanding scope of advanced molecular and cell-based diagnostic technologies within pharmaceutical quality control processes.
In January 2026, BETMAT Biotechnology launched high-performance sustainable endotoxin testing services designed to meet evolving quality control requirements in pharmaceutical and medical device manufacturing. The new service focuses on providing reliable bacterial endotoxin testing (BET) solutions that comply with international pharmacopeial standards while supporting sustainability initiatives in laboratory testing. The service launch reflects the growing demand for efficient, standardized, and environmentally responsible endotoxin-detection technologies in pharmaceutical manufacturing. BETMAT's testing infrastructure incorporates advanced automated instrumentation and strict quality management systems aligned with global pharmacopeial requirements, including USP, EP, BP, and ChP, ensuring traceable and reliable results.
Furthermore, the development of integrated testing platforms is strengthening the role of automated, standardized pyrogen-detection solutions across pharmaceutical manufacturing workflows. The NAT-MAT platform includes ready-to-use macrophage cells, nucleic acid extraction kits, and a triplex digital PCR assay, enabling reliable and automated testing for both quality control and in-process monitoring. These developments reflect the growing shift toward comprehensive testing systems that can improve efficiency and reduce manual laboratory procedures.
In addition, the ability of such technologies to support complete pyrogen and endotoxin testing creates opportunities to gradually replace traditional animal-based methods, such as the Rabbit Pyrogen Test. As regulatory agencies and industry stakeholders increasingly promote animal-free testing approaches, the adoption of advanced in vitro pyrogen detection technologies is expected to expand, thereby broadening the market scope and encouraging continued innovation in endotoxin and pyrogen and endotoxin testing solutions.
Increasing investment in R&D by the government and manufacturing companies for product development is one of the major factors contributing to the market's growth. New product development and launch is a key strategy adopted by manufacturers to maintain their dominance and to get maximum revenue share in the sector. As stated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2023, the research-based pharmaceutical industry invested around USD 48.65 billion in R&D in Europe in 2022. Hence, the need for pyrogen and endotoxin testing products is anticipated to upsurge during the forecast period.
Furthermore, the pyrogen and endotoxin testing industry is driven by the increasing demand for therapeutic drugs. Several companies are actively involved in developing new drug therapies. For instance, in 2023, the FDA approved 55 new drugs. Pyrogen testing in drug development assesses the presence or absence of pyrogens in parenteral pharmaceutical products. Moreover, the sterility of any drug does not indicate that it is pyrogen-free. Therefore, drugs that are expected to be sterile must be tested for the presence of pyrogens to control febrile reactions in patients.
Global Pyrogen And Endotoxin Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pyrogen and endotoxin testing market report based on product, technology, application, end-use, and region.
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Consumables
- Limulus Amebocyte Lysate (LAL) Endotoxin Test Kits
- Chromogenic & Turbidimetric Reagents
- Recombinant Factor C (rFC) Reagents
- Monocyte Activation Test (MAT) Kits and Reagents
- Control standard endotoxins and buffers
- Endotoxin-free Lab Consumables
- Instruments
- Endotoxin Testing Systems
- Microplate and Kinetic Readers
- Automated Endotoxin Detection Systems
- Incubators and Sample Preparation Units
- Services
- Contract Endotoxin and Pyrogen and Endotoxin Testing for IVD Manufacturers
- Method Validation and Compliance Testing
- Laboratory Contamination and Quality Assurance testing
- Technology Outlook (Revenue, USD Billion, 2021 - 2033)
- Bacterial Endotoxin Testing (BET)
- Gel Clot Method
- Chromogenic Method
- Turbidimetric Method
- Recombinant Endotoxin Detection
- Pyrogen Detection
- Monocyte Activation Test (MAT)
- Rabbit Pyrogen Test
- Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Product Safety & Batch Release Testing
- Manufacturing Process & Raw Material Control
- Validation & Regulatory Compliance Testing
- Laboratory & Clinical Environment Contamination Control
- End-use Outlook (Revenue, USD Billion, 2021 - 2033)
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Manufacturers
- Biotechnology & Life Sciences Companies
- Contract Research & Manufacturing Organizations (CROs & CDMOs)
- Clinical & Diagnostic Laboratories
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Test Type
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Technology outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Pyrogen and Endotoxin Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising production of biologics, vaccines, and injectable drugs
- 3.2.1.2. Growing investment in R&D
- 3.2.1.3. Increasing prevalence of chronic disease
- 3.2.2. Market restraint analysis
- 3.2.2.1. Stringent government regulations
- 3.2.1. Market driver analysis
- 3.3. Pyrogen and Endotoxin Testing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's
Chapter 4. Pyrogen and Endotoxin Testing Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Pyrogen and Endotoxin Testing Market, By Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
- 4.4.1. Consumables
- 4.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.1.2. Limulus Amebocyte Lysate (LAL) Endotoxin Test Kits
- 4.4.1.3. Chromogenic & Turbidimetric Reagents
- 4.4.1.4. Recombinant Factor C (rFC) Reagents
- 4.4.1.5. Monocyte Activation Test (MAT) Kits and Reagents
- 4.4.1.6. Control standard endotoxins and buffers
- 4.4.1.7. Endotoxin-free Lab Consumables
- 4.4.2. Instruments
- 4.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.2.2. Endotoxin Testing Systems
- 4.4.2.3. Microplate and Kinetic Readers
- 4.4.2.4. Automated Endotoxin Detection Systems
- 4.4.2.5. Incubators and Sample Preparation Units
- 4.4.3. Services
- 4.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.3.2. Contract Endotoxin and Pyrogen and Endotoxin Testing for IVD Manufacturers
- 4.4.3.3. Method Validation and Compliance Testing
- 4.4.3.4. Laboratory Contamination and Quality Assurance testing
- 4.4.1. Consumables
Chapter 5. Pyrogen and Endotoxin Testing Market: Technology Estimates & Trend Analysis
- 5.1. Technology Market Share, 2025 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Pyrogen and Endotoxin Testing Market, By Technology Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.4.1. Bacterial Endotoxin Testing (BET)
- 5.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.1.2. Gel Clot Method
- 5.4.1.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.1.3. Chromogenic Method
- 5.4.1.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.1.4. Turbidimetric Method
- 5.4.1.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2. Recombinant Endotoxin Detection
- 5.4.3. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.4. Pyrogen Detection
- 5.4.5. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.5.1. Monocyte Activation Test (MAT)
- 5.4.5.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.5.2. Rabbit Pyrogen Test
- 5.4.5.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.5.1. Monocyte Activation Test (MAT)
- 5.4.1. Bacterial Endotoxin Testing (BET)
Chapter 6. Pyrogen and Endotoxin Testing Market: Application Estimates & Trend Analysis
- 6.1. Application Market Share, 2025 & 2033
- 6.2. Segment Dashboard
- 6.3. Global Pyrogen and Endotoxin Testing Market, By Application Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 6.5. Product Safety & Batch Release Testing
- 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6. Manufacturing Process & Raw Material Control
- 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.7. Validation & Regulatory Compliance Testing
- 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.8. Laboratory & Clinical Environment Contamination Control
- 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Pyrogen and Endotoxin Testing Market: End Use Estimates & Trend Analysis
- 7.1. End Use Market Share, 2025 & 2033
- 7.2. Segment Dashboard
- 7.3. Global Pyrogen and Endotoxin Testing Market, By End Use Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 7.4.1. Pharmaceutical & Biopharmaceutical Companies
- 7.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.2. Medical Device Manufacturers
- 7.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.3. Biotechnology & Life Sciences Companies
- 7.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.4. Contract Research & Manufacturing Organizations (CROs & CDMOs)
- 7.4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.5. Clinical & Diagnostic Laboratories
- 7.4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.1. Pharmaceutical & Biopharmaceutical Companies
Chapter 8. Pyrogen and Endotoxin Testing Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework
- 8.5.1.3. Competitive scenario
- 8.5.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework
- 8.5.2.3. Competitive scenario
- 8.5.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.3. Mexico
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework
- 8.5.3.3. Competitive scenario
- 8.5.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.1. U.S.
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework
- 8.6.1.3. Competitive scenario
- 8.6.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.3. France
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework
- 8.6.3.3. Competitive scenario
- 8.6.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.4. Italy
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Regulatory framework
- 8.6.4.3. Competitive scenario
- 8.6.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.5. Spain
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Regulatory framework
- 8.6.5.3. Competitive scenario
- 8.6.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.6. Norway
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.7. Sweden
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Regulatory framework
- 8.6.7.3. Competitive scenario
- 8.6.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.8. Denmark
- 8.6.8.1. Key country dynamics
- 8.6.8.2. Regulatory framework
- 8.6.8.3. Competitive scenario
- 8.6.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.1. UK
- 8.7. Asia Pacific
- 8.7.1. Japan
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework
- 8.7.1.3. Competitive scenario
- 8.7.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework
- 8.7.2.3. Competitive scenario
- 8.7.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework
- 8.7.3.3. Competitive scenario
- 8.7.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.4. Australia
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.5. South Korea
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework
- 8.7.5.3. Competitive scenario
- 8.7.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.6. Thailand
- 8.7.6.1. Key country dynamics
- 8.7.6.2. Regulatory framework
- 8.7.6.3. Competitive scenario
- 8.7.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.1. Japan
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key country dynamics
- 8.8.1.2. Regulatory framework
- 8.8.1.3. Competitive scenario
- 8.8.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.2. Argentina
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.1. Brazil
- 8.9. MEA
- 8.9.1. South Africa
- 8.9.1.1. Key country dynamics
- 8.9.1.2. Regulatory framework
- 8.9.1.3. Competitive scenario
- 8.9.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.9.2. Saudi Arabia
- 8.9.2.1. Key country dynamics
- 8.9.2.2. Regulatory framework
- 8.9.2.3. Competitive scenario
- 8.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.9.3. UAE
- 8.9.3.1. Key country dynamics
- 8.9.3.2. Regulatory framework
- 8.9.3.3. Competitive scenario
- 8.9.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.9.4. Kuwait
- 8.9.4.1. Key country dynamics
- 8.9.4.2. Regulatory framework
- 8.9.4.3. Competitive scenario
- 8.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.9.1. South Africa
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2024
- 9.4. Company Profiles
- 9.4.1. Charles River Laboratories
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. bioMerieux
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Associates of Cape Cod. Inc.
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. FUJIFILM Wako Pure Chemical Corporation
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. Bioendo Technology
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. GenScript
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. ACROBiosystems
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Thermo Fisher Scientific, Inc.
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. Merck KGaA
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Sartorius AG
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.11. Eurofins Scientific
- 9.4.11.1. Company overview
- 9.4.11.2. Financial performance
- 9.4.11.3. Product benchmarking
- 9.4.11.4. Strategic initiatives
- 9.4.12. WuXi AppTec
- 9.4.12.1. Company overview
- 9.4.12.2. Financial performance
- 9.4.12.3. Product benchmarking
- 9.4.12.4. Strategic initiatives
- 9.4.1. Charles River Laboratories
(주말 및 공휴일 제외)
